Adil Doganay Duru
Adil Doganay Duru
Assistant Profesor at Nova Southeastern University
Verified email at
TitleCited byYear
Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity
CIM Dahlberg, D Sarhan, M Chrobok, AD Duru, E Alici
Frontiers in immunology 6, 605, 2015
Triticum durum metallothionein isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling
K Bilecen, UH Ozturk, AD Duru, T Sutlu, MV Petoukhov, DI Svergun, ...
Journal of Biological Chemistry 280 (14), 13701-13711, 2005
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment
K Uttervall, AD Duru, J Lund, J Liwing, G Gahrton, E Holmberg, J Aschan, ...
PLoS One 9 (7), e101819, 2014
Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice
P Brodin, T Lakshmikanth, R Mehr, MH Johansson, AD Duru, A Achour, ...
PLoS One 5 (10), e13174, 2010
Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets
E Kavak, A Najafov, N Ozturk, T Seker, K Cavusoglu, T Aslan, AD Duru, ...
Cellular signalling 22 (10), 1523-1535, 2010
Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex
C Madhurantakam, AD Duru, T Sandalova, JR Webb, A Achour
PLoS One 7 (3), e32805, 2012
Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach
E Alici, M Chrobok, J Lund, T Ahmadi, I Khan, AD Duru, H Nahi
British journal of haematology 174 (3), 473-477, 2016
Unexpected T‐cell recognition of an altered peptide ligand is driven by reversed thermodynamics
EB Allerbring, AD Duru, H Uchtenhagen, C Madhurantakam, MB Tomek, ...
European journal of immunology 42 (11), 2990-3000, 2012
The MHC Class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer
I Hafstrand, EM Doorduijn, AD Duru, J Buratto, CC Oliveira, T Sandalova, ...
The Journal of Immunology 196 (5), 2327-2334, 2016
Deletion of chromosomal region 8p21 confers resistance to Bortezomib and is associated with upregulated decoy TRAIL receptor expression in patients with multiple myeloma
AD Duru, T Sutlu, A Wallblom, K Uttervall, J Lund, B Stellan, G Gahrton, ...
PloS one 10 (9), e0138248, 2015
Autologous peripheral blood mononuclear cells as treatment in refractory acute respiratory distress syndrome
P Jungebluth, B Holzgraefe, ML Lim, AD Duru, V Lundin, N Heldring, ...
Respiration 90 (6), 481-492, 2015
The immunogenicity of a proline-substituted altered peptide ligand toward the cancer-associated TEIPP neoepitope Trh4 is unrelated to complex stability
I Hafstrand, EM Doorduijn, R Sun, A Talyzina, M Sluijter, S Pellegrino, ...
The Journal of Immunology 200 (8), 2860-2868, 2018
Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin
I Hafstrand, EC Sayitoglu, A Apavaloaei, BJ Josey, R Sun, X Han, ...
Proceedings of the National Academy of Sciences 116 (11), 5055-5060, 2019
Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer
A Parlar, EC Sayitoglu, D Ozkazanc, AM Georgoudaki, C Pamukcu, ...
European journal of immunology, 2019
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
M Chrobok, CIM Dahlberg, EC Sayitoglu, V Beljanski, H Nahi, M Gilljam, ...
Cancers 11 (1), 69, 2019
Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity
I Hafstrand, D Badia-Martinez, BJ Josey, M Norström, J Buratto, ...
PloS one 12 (12), e0189584, 2017
Lipid-based transfection reagents exhibit cryo-induced increase in transfection efficiency
H Sork, JZ Nordin, JJ Turunen, OPB Wiklander, B Bestas, EM Zaghloul, ...
Molecular Therapy-Nucleic Acids 5, e290, 2016
Lenalidomide versus lenalidomide+ dexamethasone prolonged treatment after second‐line lenalidomide+ dexamethasone induction in multiple myeloma
J Lund, A Gruber, B Lauri, AD Duru, C Blimark, A Swedin, M Hansson, ...
Cancer medicine 7 (6), 2256-2268, 2018
Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells
EC Sayitoglu, D Ozkazanc, A Sarac, A Parlar, E Alici, B Erman, AD Duru, ...
The Journal of Immunology 200 (1 Supplement), 169.19-169.19, 2018
ESGCT XXV Anniversary Congress in Collaboration with the German Society for Gene Therapy October 17–20, 2017 Berlin, Germany
SM Maffioletti, S Sarcar, A Henderson, I Mannhardt, L Pinton, LA Moyle, ...
Human Gene Therapy 28 (12), A1-A125, 2017
The system can't perform the operation now. Try again later.
Articles 1–20